Inquiry Basket
CD79b is part of the B-cell receptor (BCR) signaling complex, and a critical receptor for the successful development and maintenance of mature B cells. Antibody-drug conjugates (ADCs) are showing promise in the cancer treatment that can increase the efficacy and decrease the toxicity in comparison with traditional cytotoxic drugs. Empowered by advanced technology platforms and experienced technical personnel, BOC Sciences is fully competent and dedicated to providing your one-stop ADC development service for CD79b targets.
Served Worldwide Scientists
Synthesis Success Rate
Professional Technical Support
ADC Product Development
As part of the B cell receptor signaling complex, CD79b expression is restricted to the B-cell linage, and high expression is maintained on most subtypes of non-hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), burkitt lymphoma (BL), and follicular lymphoma (FL). The B-cell receptor is a complex formed by a surface immunoglobulin and CD79, a heterodimer containing two subunits: CD79a and CD79b. CD79 was identified in 1993 by the generation of a monoclonal antibody (SN8) recognizing its extracellular domain with a specificity for CD79b. As the SN8 antibody reacted exclusively with B cells and was internalized after binding with CD79b it was hypothesized that it could be used as an ADC in the treatment of NHL.
Fig. 1. Chemical structure of polatuzumab vedotin (Future Oncol. 2021, 17(2): 127-135).
Polatuzumab vedotin (PV) is the first-in-class ADC targeting CD79b. The efficacy of PV has been demonstrated in B-cell malignancies as a single agent and in combination with rituximab. Mechanistically, PV was generated as SN8 antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) by a protease cleavable linker. Like most ADC, when PV is bound to CD79b the complex is internalized. Once inside the cell, lysosomal proteases release the MMAE which binds to microtubules, inhibits cell division and induces apoptosis. The preclinical studies showed that a minimal expression threshold of CD79b was required for efficacy of PV on lymphoma cells.
DLBCL is one of the most common types of lymphoma in the worldwide, conventional treatment only be fit for young patients, and long-term survival is rare. New therapeutic strategies are required for refractory or relapsed patients due to limited treatment options with unsatisfying results. CD79b is expressed in almost all normal mature B cells and lymphoma cells. A study of DLBCL cell lines and early clinical trials of DLBCL patients demonstrated a significant response in both activated B-cell-like and germinal center B-cell-like subtypes. BOC Sciences now offers high-quality ADC preparation services against CD79b targets involved DLBCL to help you make progress on your ADC drug development project.
Fig. 2. Diffuse large B-cell lymphoma (DLBCL) cells.
As a professional manufacturer of ADC development, BOC Sciences provides ADC custom design services for diffuse large B-cell lymphoma (DLBCL) and other tumor treatments. Our one-stop ADC construction services include specific antibody modification and conjugation, efficient linker-payload synthesis and optimized bioconjugation strategies to obtain qualified ADCs. Various stock products related to ADC are also available. Click here for more targeted ADC development services.
References
